Christophe Jean Net Worth

The estimated Net Worth of Christophe Jean is at least $397 Tisíc dollars as of 21 June 2024. Mr. Jean owns over 3,000 units of Rhythm Pharmaceuticals stock worth over $147,930 and over the last 6 years he sold RYTM stock worth over $0. In addition, he makes $249,343 as Independent Director at Rhythm Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Jean RYTM stock SEC Form 4 insiders trading

Christophe has made over 1 trades of the Rhythm Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of RYTM stock worth $147,930 on 21 June 2024.

The largest trade he's ever made was exercising 3,000 units of Rhythm Pharmaceuticals stock on 21 June 2024 worth over $147,930. On average, Christophe trades about 375 units every 0 days since 2018. As of 21 June 2024 he still owns at least 3,000 units of Rhythm Pharmaceuticals stock.

You can see the complete history of Mr. Jean stock trades at the bottom of the page.

Christophe Jean biography

Christophe R. Jean serves as Independent Director of the Company. Mr. Jean has served as a member of our Board since 2015. He is currently a Strategic Advisor for Oraxys S.A., a private equity firm, a role he has held since June 2019. Mr. Jean also served as a Senior Advisor for JSB Partners, LLC, a specialized biotechnology and pharmaceutical investment banking and advisory services firm, from November 2018 until December 2019. Previously, Mr. Jean served as Executive Vice President of Corporate Strategy, Business Development, Alliances and M&A for Ipsen S.A., a pharmaceutical company, from 2013 until his retirement in July 2018, after serving for 11 years in the position of Executive Vice President, Chief Operating Officer, with responsibility for all commercial operations and medical affairs worldwide as well as Ipsen S.A.'s therapeutic area franchises. Prior to joining Ipsen S.A., Mr. Jean was President and CEO for the pharmaceutical activities of the Pierre Fabre Group and President of Europe, Middle East, and Africa for Novartis Pharma AG's Pharmaceutical Division. Prior to the merger of Ciba-Geigy AG and Sandoz Inc. that formed Novartis Pharma AG, he held a number of marketing and management positions in Europe and Latin America for Ciba-Geigy AG, culminating as Head of Finance and IT Worldwide and Member of the Pharma Executive Committee. Mr. Jean is a member of the boards of directors of private companies Keosys SAS and Bcell Therapeutics. He holds an M.B.A. from Harvard Business School.

What is the salary of Christophe Jean?

As the Independent Director of Rhythm Pharmaceuticals, the total compensation of Christophe Jean at Rhythm Pharmaceuticals is $249,343. There are 11 executives at Rhythm Pharmaceuticals getting paid more, with Hunter Smith having the highest compensation of $1,922,850.

How old is Christophe Jean?

Christophe Jean is 64, he's been the Independent Director of Rhythm Pharmaceuticals since 2015. There are 4 older and 14 younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals Inc. is Dr. David P. Meeker M.D., 67, who is the Chairman, Pres & CEO.

What's Christophe Jean's mailing address?

Christophe's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.

Insiders trading at Rhythm Pharmaceuticals

Over the last 13 years, insiders at Rhythm Pharmaceuticals have traded over $83,445,563 worth of Rhythm Pharmaceuticals stock and bought 6,290,000 units worth $106,961,700 . The most active insiders traders include Forest Baskett, Scott D Sandell a Peter J Barris. On average, Rhythm Pharmaceuticals executives and independent directors trade stock every 17 days with the average trade being worth of $3,358,405. The most recent stock trade was executed by Pamela J. Cramer on 9 September 2024, trading 4,099 units of RYTM stock currently worth $77,963.

What does Rhythm Pharmaceuticals do?

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.

Complete history of Mr. Jean stock trades at Rhythm Pharmaceuticals

Rhythm Pharmaceuticals executives and stock owners

Rhythm Pharmaceuticals executives and other stock owners filed with the SEC include:

• Hunter Smith,
  Chief Financial Officer
• Dr. David P. Meeker M.D.,
  Chairman, Pres & CEO
• Yann Mazabraud,
  Exec. VP & Head of International
• Hunter C. Smith M.B.A.,
  CFO & Treasurer
• Hunter C. Smith,
  CFO, Treasurer & Sec.
• Jennifer L. Chien,
  Exec. VP & Head of North America
• Joseph Shulman,
  Chief Technical Officer
• Jennifer Good,
  Independent Director
• Stuart Arbuckle,
  Independent Director
• David Meeker,
  Chairman of the Board, President, Chief Executive Officer
• David McGirr,
  Independent Director
• Christophe Jean,
  Independent Director
• Todd Foley,
  Independent Director
• Edward Mathers,
  Independent Director
• Dr. David P. Meeker,
  Chairman, Pres & CEO
• Yann Mazabraud,
  Executive Vice President, Head of International
• Hannah Deresiewicz,
  IR Contact Officer
• Pamela Cramer,
  Chief HR Officer
• Sarah Ryan,
  VP of Sales & Marketing
• William T. Roberts,
  Chief Accounting Officer
• Dr. Alastair Garfield Ph.D.,
  VP & Head of Research
• Dr. Murray W. Stewart M.D.,
  Chief Medical Officer
• Simon D. Kelner,
  Chief HR Officer
• Satej Bhandarkar,
  Sr. VP of Program Management, Strategy & Corp. Devel.
• Jim Flaherty,
  Sr. VP & Gen. Counsel
• David Connolly,
  Head of Investor Relations & Corp. Communications
• Rock Ventures Lp Third Rock...,
  
• Fred T. Fiedorek,
  Chief Medical Officer
• Nithya Desikan,
  Chief Commercial Officer
• Der Ploeg Leonardus H.T. Van,
  Chief Scientific Officer
• Neil Exter,
  Director
• Rock Ventures Lp Third Rock...,
  
• Bioventures V, L.P.Evnin Lu...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 13 Lp...,
  
• Inc Pfizer,
  10% owner
• S.A. Ipsen,,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Jonathan Silverstein,
  Director
• Harbor Master Investors (Ca...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Bros. Advisors Lp Baker Bro...,
  
• Simon Kelner,
  Chief Human Resources Officer
• Murray Stewart,
  Chief Medical Officer
• Advisors Llc Orbi Med Capit...,
  
• William T. Roberts,
  Chief Accounting Officer
• Keith Michael Gottesdiener,
  CEO & President
• Capital Management, L.P.Ra ...,
  
• Jennifer Kayden Lee,
  EVP, Head of North America
• Joseph Shulman,
  Chief Technical Officer
• Lynn A. Tetrault,
  Director
• Pamela J. Cramer,
  Chief Human Resources Officer
• Linda Shapiro Manning,
  Chief Medical Officer
• Christopher Paul German,
  Corporate Controller & CAO
• Alastair Garfield,
  Chief Scientific Officer